BCMA-CD19 cCAR T cells not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy”In the company’s words, NCT04162353 on ClinicalTrials.gov
- Tested for
- Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Plasmacytoid; Lymphoma, Refractory Immune Cytopenia
- Main trialPhase 1
- “This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.”In the company’s words, NCT04162353 on ClinicalTrials.gov
Other drugs for Multiple Myeloma in Relapse
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jul 2026 | BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma | |
| Phase 1Recruiting | Aug 2026 | BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases | |
| Phase 1Unknown | 30 Apr 2025 | BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026